4 7 1 t e C h n I C a l r e p O r t S Rapid and reversible methods for altering the levels of endogenous proteins are critically important for studying biological systems and developing therapeutics. Here we describe a membrane-permeant targeting peptide-based method that rapidly and reversibly knocks down endogenous proteins through chaperone-mediated autophagy in vitro and in vivo. We demonstrate the specificity, efficacy and generalizability of the method by showing efficient knockdown of various proteins, including death associated protein kinase 1 (160 kDa), scaffolding protein PSD-95 (95 kDa) and a-synuclein (18 kDa), with their respective targeting peptides in a dose-, time-and lysosomal activity-dependent manner in rat neuronal cultures. Moreover, we show that, when given systemically, the peptide system efficiently knocked down the targeted protein in the brains of intact rats. Our study provides a robust and convenient research tool for manipulating endogenous protein levels and may also lead to the development of protein knockdown-based therapeutics for treating human diseases.
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Techniques that regulate the level of protein expression by targeting genes at the DNA or RNA level have proven to be powerful strategies in the drive to understand protein expression and function [1] [2] [3] . However, because of their very nature, these techniques are restricted in terms of speed, specificity and reversibility 4 . For instance, these genetic methods of disrupting protein expression can take days to weeks; consequently, cellular and molecular compensation may occur, thereby obscuring expected phenotypes. In addition, as these genetic manipulations result in the eradication of all mRNA splice isoforms, as well as post-translationally modified versions of targeted proteins 5 , these methods lack specificity and are largely limited to studying contextdependent protein function. Finally, the reversibility of these genetic manipulations, including many recently developed on-and-off inducible methods, is relatively slow (being achieved on a timescale of days to weeks) and is incomplete. These limitations, in turn, severely constrain the potential of these methods as both research tools and clinical therapeutics.
To overcome shortcomings of DNA-and mRNA-based protein manipulations, several laboratories have recently attempted to harness cellular protein degradation systems to reduce levels of proteins of interest (POIs) [6] [7] [8] [9] [10] [11] . However, most of these proposed systems require genetic manipulations of the proteins to facilitate their targeting and degradation by means of specific cellular protein degradation systems. Hence their usefulness for knocking down unmodified native proteins in primary cells is limited. Moreover, most of these methods require viral delivery in vivo, thus limiting their potential for clinical use.
Here we propose a simple, non-virally mediated, cell membranepermeant, targeting peptide-based system to rapidly and reversibly knock down an endogenous POI by targeting it for lysosomal degradation. We demonstrate its efficacy, specificity and broad utility by targeting three native proteins in primary neuronal cultures. In each case, degradation was substantial within hours of applying the targeting peptides. Depending on the nature of the interaction between the targeting peptide and the protein target, the knockdown could be either constitutive or conditional. Moreover, we found that our peptide system was able to efficiently knock down a native neuronal protein in the brains of intact animals when the targeting peptide was given systemically. Our method can be easily generalized to degrade any native cytosolic POI. It offers a simpler, faster and more easily reversible alternative to current chemical-genetic protein degradation methods and is suitable for both in vitro and in vivo use, as well as for translation into therapies.
RESULTS

Knockdown of recombinant proteins in HEK cells
Chaperone-mediated autophagy (CMA) is a type of autophagy specific for proteins containing a pentapeptide motif biochemically related to KFERQ 12 . This CMA-targeting motif (CTM) is found in all known proteins that are substrates of CMA 13 . Previous studies with KFERQ-containing fusion proteins demonstrated that the attachment of a CTM is necessary and sufficient to make non-CMA fluorescent substrates amenable to CMA, provided it is exposed 14 . Thus, to utilize CMA as our degradation pathway to knock down endogenous proteins, we designed a targeting peptide consisting of three domains (Supplementary Fig. 1a) : a cell membrane-penetrating domain (CMPD) that allows the peptide to bypass the blood-brain barrier and plasma membrane following peripheral delivery, a proteinbinding domain (PBD) that specifically binds to the endogenous POI through peptide-protein interaction and the CTM that targets the peptide-protein pair for degradation through the lysosomal t e C h n I C a l r e p O r t S proteolytic machinery. We hypothesized that the targeting peptide, when applied to a cellular environment in vitro or in vivo, would enter the cell via its CMPD, where it would specifically recognize and form a stable complex with its target protein via the PBD, and, through interactions between the CTM and CMA machinery, deliver the peptide-protein complex to the lysosomal compartment for rapid knockdown (Supplementary Fig. 1a ).
Using an overexpression system, we first tested whether our proposed CTM, when fused to a non-CMA substrate protein, efficiently directed the protein into the lysosome for degradation. To increase targeting efficiency, we simultaneously tagged green fluorescent protein (GFP) with three CTMs identified from CMA substrate proteins: RNase A (KFERQ) 15 , hsc70 (QKILD) 16 and hemoglobin (QRFFE) 17 (Fig. 1a) . We then transiently expressed the CTM-GFP construct, along with wild-type GFP construct (WT-GFP) as a control, in human embryonic kidney (HEK) or African green monkey fibroblast-like kidney cells (COS-7 cells). As is consistent with the ability of the CTM to direct CTM-GFP for lysosomal degradation, immunoblot analysis showed that CTM-GFP protein levels were decreased ( Fig. 1b ) and that this decrease occurred in a time-dependent manner ( Supplementary Fig. 1b ). Coimmunofluorescence staining revealed diffuse expression of WT-GFP (n = 17 cells) in most compartments of the cell, including the nucleus (Fig. 1c) . By contrast, CTM-GFP (n = 16 cells) was predominantly directed to the lysosome, as evidenced by its high degree of colocalization with the lysosome marker protein LAMP-1. Quantification demonstrated a significant increase in colocalization of GFP and LAMP-1 signals, from 33.6 ± 3.6% to 79.1 ± 1.4%, by inclusion of the CTM (mean value ± s.e.m.; P < 0.001; Mann-Whitney rank-sum test, t = 408; cells from 3 separate transfections).
Several lines of evidence further support the idea that the reduction of CTM-GFP levels is a result of increased lysosomal targeting and degradation. First, CTM-GFP degradation was significantly prevented by treatment with ammonium chloride (20 mM), which inhibits lysosome degradation 18 (82.65% ± 6.28%; n = 6 individual experiments; P < 0.001) and pepstatin A (10 µM; 106.98% ± 6.68%; n = 5 individual experiments; P < 0.001), which inhibits the two primary lysosomal proteases, cathepsins D and E 19, 20 (Fig. 1b) . In contrast, inhibition of macroautophagy with 3-methyladenine (10 mM; P = 0.951) or proteasomal degradation with MG132 (5 µM; P = 0.194) did not prevent reduction of CTM-GFP ( Fig. 1b) . Second, CMA can be activated or enhanced under conditions of stress, such as starvation induced by removal of serum in culture media 21 . Serum deprivation enhanced CTM-GFP degradation (23.95% ± 5.94% of WT-GFP level; n = 5 individual experiments; P < 0.001) ( Fig. 1b) . Third, mutation of the glutamine residues in the CTM of CMA substrate proteins impairs their targeting into the lysosomal lumen and degradation through CMA 22 . Accordingly, mutating two glutamines in the CTM of CTM-GFP into alanines (mCTM-GFP) significantly rescued its degradation ( Fig. 1b ; mCTM-GFP; 86.85% ± 6.18% of WT-GFP; n = 6 individual experiments; P = 0.075). Finally, overexpressing CTM-GFP did not substantially alter the stability of the endogenous CMA substrate glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 23 ( Supplementary  Fig. 1b ), suggesting that CTM-GFP overexpression did not induce pan-activation of CMA in transfected cells. Together, this data is in line with recent evidence 14 showing that the addition of CTM to a non-CMA substrate protein is sufficient to specifically channel the protein for degradation through the CMA pathway.
We next examined whether a non-CMA substrate protein could be indirectly tagged for CMA lysosomal degradation by a targeting peptide containing the CTM and the PBD through an interaction between the protein and the targeting peptide. Death-associated protein kinase 1 (DAPK1) is a calcium-calmodulin-regulated protein kinase normally inactive in the brain 24 . Under certain pathological conditions, such as excitotoxic stimulation with NMDA or cerebral ischemia 25 , DAPK1 can be activated and recruited into the NMDAtype glutamate receptor complex by its interaction with C-terminal residues 1292-1304 of the NMDA receptor (NMDAR) GluN2B subunit (GluN2Bct 1292-1304 ) 26 . Because GluN2B can bind only the active and not the inactive form of DAPK1, we hypothesized that a targeting peptide composed of the DAPK1 binding domain of the GluN2B and CTM would specifically knock down active DAPK1 by targeting it for CMA lysosomal degradation. Therefore, we designed two GluN2B C-terminal tail constructs bearing an influenza hemagglutinin (HA) tag, the C-terminal fragment of GluN2B (GluN2Bct 1242-1342 ) containing the required sequence for binding to DAPK1, and either a functional CTM (HA-GluN2Bct-CTM) or a nonfunctional, mutated form of CTM (HA-GluN2Bct-CTMm) ( Fig. 2a) .
We first coexpressed HA-GluN2Bct-CTMm (resistant to lysosomal degradation and hence more stable than HA-GluN2Bct-CTM) with either a Flag-tagged constitutively active form of DAPK1 (cDAPK1) 27 or wild-type DAPK1 (wtDAPK1) in HEK cells to assess DAPK1 activity-dependent binding between DAPK1 and the GluN2B (b) Quantification of CTM-GFP and mCTM-GFP relative to WT-GFP in HEK cells 24 h after individual transfections with WT-GFP, mCTM-GFP (n = 6) or CTM-GFP. Cells transfected with WT-GFP or CTM-GFP were treated without (no treatment; n = 13) or with serum deprivation (+ SD; n = 5; to enhance CMA activity) or with macroautophagy inhibitor 3-methyladenine (+ 3-MA; 10 mM; n = 5), proteasome inhibitor (+ MG132; 5 µM; n = 6), lysosome inhibitor (+ NH 4 Cl; 20 mM; n = 6) or pepstatin A (+ Pep A; 10 µM; n = 5). Top, representative immunoblots of cell lysates for GFP. Membranes reprobed for β-actin were used as a loading control. Bottom, means ± s.e.m. of relative protein levels, normalized to WT-GFP (arbitrarily set as 1; white bar); n represents the number of independent experiments from at least 4 separate cultures. One-way ANOVA with Fisher least significant difference test, F(12,73) = 20.939. ***P < 0.001 versus WT-GFP (white bar); ∆∆∆ P < 0.001 relative to untreated CTM-GFP levels (gray bar). Full-length blots are presented in Supplementary Figure 9 . Fig. 2b) revealed interaction between HA-GluN2Bct-CTMm and cDAPK1 but not wtDAPK1, confirming previous results that binding between GluN2B and DAPK1 is conditional on the activation of the latter 26 . Coexpression of HA-GluN2Bct-CTM at various ratios efficiently decreased, in a dose-dependent manner, the levels of cDAPK1 assessed 24 h after transfection ( Fig. 2c) . At a 2:1 transfection ratio, cDAPK1 levels were decreased by 29.18 ± 1.91% of those obtained when cDAPK1 was transfected alone (n = 4 individual experiments; P = 0.021), whereas at 8:1, cDAPK1 levels were reduced by 92.85% ± 2.30% (n = 4 individual experiments; P = 0.001). In contrast, coexpression of the HA-GluN2Bct-CTM with wtDAPK1 at even the highest ratio (8:1) did not significantly affect wtDAPK1 protein levels compared to wtDAPK1 transfected alone ( Fig. 2d ; n = 3 individual experiments; P = 0.933), strongly suggesting that the ability of the targeting peptide to interact with DAPK1 is required for the peptideinduced cDAPK1 degradation. cDAPK1 degradation appeared to be mediated by the lysosome, as it was significantly prevented by the lysosomal inhibitor NH 4 Cl ( Fig. 2c ; n = 4 individual experiments) or by mutating the CTM in the targeting peptide ( Fig. 2e ; HA-GluN2Bct-CTMm; from at least 7 individual experiments; P = 0.785 compared to HA-GluN2Bct-CTMm transfected alone). Taken together, these data suggest that the specific reduction of cDAPK1, but not wtDAPK1, depends on the targeting peptide-protein interaction and on an intact CTM in the targeting peptide, and is mediated by the lysosome.
Knockdown of native proteins in primary neuronal cultures
The above results demonstrate that a targeting peptide comprising a specific PBD and CTM can target its binding partner for lysosomal degradation in a dose-, time-and condition-dependent manner in recombinant expression systems. We next tested whether targeting peptides can efficiently knock down non-genetically modified, native proteins in cultured rat cortical neurons. As previously reported 26 , treatment with 50 µM NMDA for 30 min resulted in the activation of DAPK1 ( Fig. 3a, left) , as evidenced by a decrease in the phosphorylated form of DAPK1 (ref. 26) , as well as a notable reduction in the total amount of DAPK1 (consistent with a previous report 25 ). We found no obvious association between GluN2B and DAPK1 under basal conditions using coimmunoprecipitation. However, NMDA treatment resulted in complex formation between the two proteins ( Fig. 3a, right) , consistent with previously reported activation and recruitment of DAPK1 to NMDARs by NMDA stimulation 26 . This activity-dependent association between GluN2B and DAPK1 suggests a potential use for our GluN2Bct-CTM construct (described above) to knock down DAPK1 in an NMDA-dependent manner. Thus, we subcloned the GluN2Bct-CTM (using GluN2Bct as a control) along with the cell membrane-penetrating sequence TAT 28 into bacterial expression vectors and then expressed and purified them as His-tagged recombinant peptides (TAT-GluN2Bct-CTM and TAT-GluN2Bct; Fig. 3b ). When bath-applied on its own, TAT-GluN2Bct-CTM (200 µM; n = 4 individual experiments; P = 0.47) produced no observable effect on the basal level of DAPK1 ( Fig. 3c) . However, when applied with NMDA, TAT-GluN2Bct-CTM (200 µM; 60 min before and during 30 min NMDA treatment) decreased DAPK1 by 57.50% ± 6.70%, 2 h after NMDA washout (n = 9 individual experiments; P = 0.007; Fig. 3c ), an effect blocked by concomitant treatment with the lysosome inhibitor NH 4 Cl. In contrast, coapplication of the Reciprocal coimmunoprecipitation (IP) followed by immunoblotting revealed that GluN2Bct specifically interacted with cDAPK1 but not wtDAPK1. Flag-tagged inactive wtDAPK1 or constitutively active cDAPK1 was expressed with either HA-GluN2Bct-CTM or HA-GluN2Bct-CTMm at various ratios in HEK cells, and coimmunoprecipitation and/or immunoblotting were performed 24 h thereafter. Anti-HA was used to detect HA-GluN2Bct-CTM and HA-GluN2Bct-CTMm, anti-FLAG to detect wtDAPK1 and cDAPK1. npg t e C h n I C a l r e p O r t S same amount of control peptide TAT-GluN2Bct with NMDA did not produce any noticeable reduction of DAPK1 relative to NMDA treatment alone (Fig. 3c) . These results strongly suggest that the observed decrease in DAPK1 is mediated by lysosomal degradation and that it requires the specific interaction of GluN2Bct with the activated DAPK1 and the presence of the CTM in the targeting peptide.
More detailed analyses revealed that, following NMDA stimulation ( Fig. 3d) , increasing TAT-GluN2Bct-CTM from 25 µM to 200 µM produced dose-dependent DAPK1 degradation (n = 4 individual experiments). Furthermore, a single dose of TAT-GluN2Bct-CTM (200 µM; 60 min before and 30 min during NMDA stimulation) resulted in a time-dependent reduction in DAPK1, which became significant by 2 h, peaked at 4 h and then gradually returned to baseline by 7 h after treatment ( Fig. 3e) . However, administering a second dose of TAT-GluN2Bct-CTM immediately after NMDA washout allowed DAPK1 degradation to persist up to 7 h ( Fig. 3f ; n = 4 individual experiments; P = 0.002). Notably, the levels of mRNA were not affected ( Supplementary Fig. 2) . The reversibility and time dependency of DAPK1 degradation strongly support the supposition that the degradation is not due to nonspecific cellular processes, such as toxicity-induced cell death, but is a result of TAT-GluN2Bct-CTMmediated knockdown. Notably, our results indicate that varying the concentrations and/or times of targeting peptide applications can easily control the degree and the duration of POI degradation, allowing fine-tuned control of expression of the endogenous POI.
Although TAT-GluN2Bct-CTM can be easily produced in recombinant expression systems, the 100 amino acids in the GluN2B C terminus contain multiple proteolytic sites 29 , making it vulnerable to fast clearance from the cell, lowering its bioavailability, and increasing the chance of off-target effects. Because the binding of GluN2B to activated DAPK only requires the 18 amino acid residues of GluN2B 1292-1340 (ref. 26) , we next hypothesized that a short synthetic form of the targeting peptide containing this binding sequence, the membrane-permeant TAT and the CTM should be sufficient to target active DAPK1 to lysosomes for degradation. Hence we synthesized the targeting peptide TAT-GluN2BCTM and its control TAT-GluN2B ( Fig. 3g) . Bath application of TAT-GluN2BCTM (25 µM) resulted in significant reduction of DAPK1 following NMDA treatment (n = 5; P = 0.001 compared to NMDA-treated group), an effect that was rescued by NH 4 Cl, while TAT-GluN2B did not affect DAPK1 levels (Fig. 3h) . Furthermore, subcellular fractionation analysis showed that, despite a rapid increase of DAPK1 in the mitochondria following NMDA stimulation, TAT-GluN2BCTM was able to reduce the levels of DAPK1 in nuclear, cytosolic and mitochondrial fractions ( Supplementary Fig. 3 ). Short interfering RNA-mediated knockdown of LAMP-2A, a crucial component of the CMA machinery, significantly (n = 4 individual experiments, P < 0.001 compared to NMDA-treated group) rescued DAPK1 knockdown ( Supplementary  Fig. 4) , further supporting the role of lysosome-dependent degradation.
To determine whether other cell-penetrating peptides could replace TAT to make our method more generalizable, we further synthesized the small peptide GluN2B-CTM ( Supplementary Fig. 5a ) without a physically linked CMPD. To deliver GluN2B-CTM into the cell interior, we mixed GluN2B-CTM with the intracellular delivering carrier peptide Pep-1 (ref. 30 ) at a 1:4 ratio for 30 min to form a plasma membrane-permeant peptide complex 30, 31 . We then bath-applied the complex to neurons for 60 min before and during NMDA (50 µM; 30 min) treatments. Bath application npg t e C h n I C a l r e p O r t S of the complex degraded activated DAPK1 in a dose-and time-dependent manner through the lysosome (Supplementary Fig. 5b-d) . Taken together, the above data illustrate the reliability and specificity of DAPK1-targeting peptides (His-tagged recombinant peptide, TAT-or Pep-1-mediated synthetic peptides) to rapidly and reversibly degrade its endogenous binding partner DAPK1 in primary neuronal cultures in a dose-, time-and activity-dependent manner.
Having confirmed the success of our targeted peptide-mediated DAPK1 degradation approach, we next assessed the generalizability of our method by targeting two other native neuronal proteins, α-synuclein and postsynaptic density protein 95 (PSD-95). α-synuclein, a protein implicated in neurodegenerative synucleinopathies such as Parkinson's disease 32 , was recently found to strongly interact with a short amino acid stretch (amino acids 36-45) of β-synuclein (βsyn36) 33 . Therefore, we designed a targeting peptide containing βsyn36 and the CTM (TAT-βsynCTM; Fig. 4a, top) to target α-synuclein. PSD-95 is a membrane-associated guanylate kinase concentrated at glutamatergic synapses and is involved in synapse stabilization and plasticity. PSD-95 acts as a scaffold to assemble a specific set of signaling proteins around the NMDAR and binds to nine amino acids at the GluN2B subunit C-terminal tail 34 (GluN2B9c). We therefore synthesized the PSD-95 targeting peptide TAT-GluN2B9cCTM (Fig. 4b, top) . We hypothesized that TAT-βsynCTM and TAT-GluN2B9cCTM, but not their respective controls (TAT-βsyn and TAT-GluN2B9c), would be sufficient to target α-synuclein and PSD-95, respectively, for degradation. Indeed, TAT-βsynCTM (25 µM; n = 5 individual experiments; P < 0.001), but not its control TAT-βsyn (25 µM; n = 5 individual experiments), when bath applied, significantly degraded native α-synuclein in primary cultured neurons, without affecting the nontarget PSD-95 (Fig. 4a, middle and bottom) . The knockdown was rescued by concomitant treatment with the lysosome inhibitor NH 4 Cl (Fig. 4a, middle) , but not by inhibition of macroautophagy with 3-methyladenine ( Supplementary Fig. 6 ). Conversely, TAT-GluN2B9cCTM (25 µM; n = 4 individual experiments; P < 0.01), but not its control TAT-GluN2B9c (25 µM; n = 4 individual experiments), significantly reduced PSD-95 but not α-synuclein in a lysosome-dependent fashion (Fig. 4b) .
As α-synuclein harbors an endogenous CMA targeting motif ( 95 VKKDQ 99 ) 22 , TAT-βsynCTM could be enhancing its accessibility or functioning in an additive manner. To determine whether the targeting peptide sufficiently directs α-synuclein for lysosomal degradation independent of its endogenous CMA targeting motif, we mutated the endogenous motif to produce α-synuclein(∆DQ). Following transfection into HEK293 cells, treatment with TAT-βsynCTM significantly reduced the level of α-synuclein(∆DQ) (n = 4 individual experiments, P = 0.006), an effect that was rescued by NH 4 Cl ( Supplementary  Fig. 7) . Finally, TAT-βsynCTM also decreased the levels of the A53T variant of α-synuclein ( Supplementary Fig. 7) , which is present in some forms of familial Parkinson's disease. Notably, none of the peptides showed apparent toxicity at the concentrations used, even after 24 h of application (Supplementary Fig. 8 ). Together, these results indicate that the targeting peptide-mediated degradation is specific for its targeted protein and that targeting peptide can be generalized to degrade in situ most, if not all, native cytosolic proteins, as well as some of their pathological variants.
Neuroprotection by DAPK1 knockdown in vitro and in vivo
Having shown the reliability of a targeting peptide to degrade a variety of native proteins, we next asked whether targeting peptide-mediated knockdown can have physiologically and/or pathologically relevant phenotypes. As mentioned above, DAPK1 is a cell deathpromoting protein kinase in many cell types and is known to be required for cell death under pathological conditions such as stroke. npg t e C h n I C a l r e p O r t S It has previously been shown that, following ischemic insult, overactivation of NMDARs activates and recruits DAPK1 to the GluN2B C terminus of the NMDAR. Dissociation of DAPK1 from the NMDAR by administration of the membrane-permeant GluN2B peptide without CTM (TAT-GluN2B) not only prevents NMDA-induced neuronal damage but also partially reduces ischemic brain injuries in an animal model of stroke 26 . Stroke-induced ischemic neuronal damage can also occur through mechanisms other than NMDAR-mediated excitotoxicity, including oxidative stress 35 . Previous results have revealed that DAPK1 is a central mediator of oxidative stress-induced cell death 36 . Therefore, we reasoned that, in comparison with the TAT-GluN2B (without CTM) that reduces NMDAR-mediated excitotoxicity by disrupting the DAPK1-NMDAR interaction 26 , our targeting peptide TAT-GluN2BCTM, by knocking down DAPK1, may protect neurons against not only NMDAR-mediated excitotoxicity but also other neuronal damage signaling pathways including oxidative stress.
We first tested the idea that knocking down DAPK1 can protect neurons against NMDAR-independent, oxidative stress in primary neuronal cultures. Exposure of cultured cortical neurons to H 2 O 2 (300 µM; 30 min), a potent generator of oxidative stress-inducing reactive oxygen species 37 , activated DAPK1 as demonstrated by timedependent decrease in levels of DAPK1 phosphorylation (Fig. 5a) . Pretreatment of these neurons with TAT-GluN2Bct-CTM (100 µM), but not TAT-GluN2Bct, resulted in a more than 60% reduction in DAPK1 level in H 2 O 2 -treated (but not control) neurons (reduced to 36.54 ± 7.1%; n = 8 individual experiments; P = 0.001 compared with non-H 2 O 2 -treated control. This reduction was prevented by coapplication of NH 4 Cl (Fig. 5b) . A lactate dehydrogenase (LDH)based cell death assay revealed that H 2 O 2 exposure significantly increased neuronal death (n = 4 individual experiments; 2.38 ± 2.70; P = 0.001), an effect that was rescued by catalase, an enzyme that breaks down H 2 O 2 (Fig. 5c) 37 . By contrast, treatment with the selective NMDAR antagonist (2R)-amino-5-phosphonovaleric acid (APV; 1 mM) did not protect against H 2 O 2 -induced neurotoxicity, consistent with the idea that this H 2 O 2 -mediated neuronal damage is not mediated by NMDARs. In support of our hypothesis, TAT-GluN2Bct-CTM (50 µM; 60 min before and continuously present during and following H 2 O 2 washout; n = 9 individual experiments), but not TAT-GluN2Bct, significantly (P < 0.001) reduced H 2 O 2induced neurotoxicity. Furthermore, concurrent treatment with the lysosome inhibitor NH 4 Cl inhibited the neuroprotective effect of TAT-GluN2Bct-CTM (n = 4 individual experiments), supporting neuroprotection mediated by TAT-GluN2Bct-CTM-induced lysosomal degradation of DAPK1. However, as NH 4 Cl may inhibit the degradation of DAPK1 in the lysosome without affecting its translocation to the lysosomal lumen, an unrelated toxic effect from NH 4 Cl remains to be ruled out. Together, the results indicate that TAT-GluN2Bct-CTM is neuroprotective against non-NMDAR-dependent oxidative stress and that this neuroprotective effect is a result of the peptide-mediated lysosomal degradation of DAPK1.
We next examined whether systemic application of TAT-GluN2BCTM could knock down DAPK1, thereby producing neuroprotection against ischemic insult in vivo in a well-characterized rat model of focal ischemia, middle carotid artery occlusion (MCAo), that was previously shown to reliably activate DAPK1 in vivo 26 . To measure the efficacy of DAPK1 knockdown using both immunoblot and immunocytochemistry, we used a relatively mild (60 min unilateral occlusion) ischemic insult. Rats subjected to 60 min of MCAo were injected intravenously (i.v.) with either saline, TAT-GluN2BCTM or TAT-GluN2B 1 h after reperfusion (Fig. 6a). 2,3 ,5-Triphenyltetrazolium chloride staining of transverse brain sections from saline-treated rats revealed that unilateral MCAo reliably induced ischemic brain damage, mostly in the ipsilateral striatum (Fig. 6b) . As DAPK1 is activated by MCAo-induced ischemic stimulation 26 and the TAT-GluN2BCTM knockdown of DAPK1 is DAPK1-activation dependent, we reasoned that DAPK1 would be maximally activated and degraded in regions most affected by ischemic insult. To determine ischemia-induced knockdown of DAPK1 by TAT-GluN2BCTM, ; P = 0.001), but not TAT-GluN2Bct (89.13 ± 10.78%; n = 7; P = 0.311), 60 min before and during H 2 O 2 treatment (300 µM; 30 min) knocked down DAPK1 at 2 h after washout, and this effect was rescued by NH 4 Cl (20 mM; n = 8; **P = 0.003 to control; P = 0.106 to H 2 O 2 -treated). One-way ANOVA, F(4,34) = 11.628, P < 0.001. Bars represent DAPK1 levels relative to saline control group. β-actin was used as a loading control. (c) LDH assay revealed that H 2 O 2 treatment (300 µM; 30 min) resulted in a significant increase in neuronal death 12 h after treatment (n = 8; 2.50 ± 0.12; P < 0.001 to control), which was rescued by breaking down H 2 O 2 with catalase (100 U in 10 µl phosphate-buffered saline; n = 4; 1.17 ± 0.02; P = 0.001 to H 2 O 2 group). H 2 O 2 -induced neurotoxicity was significantly reduced by TAT-GluN2Bct-CTM (50 µM; applied 60 min before and maintained throughout the experiments; n = 9; 1.56 ± 0.08; P = 0.001 to H 2 O 2 group), but not by TAT-GluN2Bct (50 µM; n = 9; 2.63 ± 0.10; P = 0.105 to H 2 O 2 group) or the NMDAR antagonist APV (1 µM; n = 4; 2.16 ± 0.14; P = 0.169 to H 2 O 2 group). NH 4 Cl abolished the neuroprotective effect of TAT-GluN2Bct-CTM (n = 4; 2.39 ± 0.27; P = 0.538 compared to H 2 O 2 group). One-way ANOVA, P < 0.001, F(6,41) = 26.842. *** ,∆∆∆ P < 0.001; bars represent relative mean values ± s.e.m. normalized to the saline control (white bar, arbitrarily set as 1). n represents individual experiments from at least 3 separate primary cultures. Full-length blots are presented in Supplementary Figure 9 . npg t e C h n I C a l r e p O r t S we excised tissues from both MCAochallenged and contralateral sides of the striatum and nearby cortex ( Fig. 6c) and immunoblotted for DAPK1. Whereas TAT-GluN2B (10 mg per kilogram body weight, i.v.) produced no obvious change in the levels of DAPK1 in the brain tissues of either ischemic or contralateral side, TAT-GluN2BCTM (10 mg per kilogram, i.v.) resulted in a significant reduction in DAPK1 only in the ischemic side of the brain: DAPK1 was reduced to 43.3% of that on the contralateral side ( Fig. 6d ; P < 0.001, n = 3 individual experiments; two-tailed Student's t-test).
Given that the collected tissues included some non-infarct areas (Fig. 6c) , the actual efficiency of targeting peptide-mediated knockdown would be expected to be even greater.
To further assess region-specific DAPK1 degradation in a more direct manner, we used immunohistochemistry to probe for DAPK1 in transverse brain sections (Fig. 6e,  right) . As expected, DAPK1 knockdown was specific to strokedamaged areas, as visualized with hematoxylin and eosin (H&E) staining (Fig. 6e, left) of the adjacent sections. This further confirmed our in vitro results demonstrating that TAT-GluN2BCTM is capable of specific knockdown of the active and not inactive form of DAPK1. To our knowledge, this is the first evidence for such a disease-specific protein knockdown in intact animals. The specific knockdown of DAPK1 by TAT-GluN2BCTM was associated with a much more significant reduction of the infarct area, in comparison with that of TAT-GluN2B, which partially decreased ischemic damage by uncoupling DAPK1 from the GluN2B receptor signaling complex, as previously reported 26 . We further confirmed the more prominent neuroprotective effects of TAT-GluN2BCTM-mediated DAPK1 knockdown by quantifying numbers of degenerating neurons in both striatum and cortex. For this purpose, we used Fluorojade B, a common stain that labels degenerating cells; it is suitable for assessment of cellular injury following MCAo 38, 39 . Consistent with the results of H&E staining (Fig. 6e, left) , Fluorojade B staining showed that while both npg t e C h n I C a l r e p O r t S TAT-GluN2B and TAT-GluN2BCTM significantly reduced the numbers of degenerating neurons in both striatum and cortical areas, the neuroprotective effect of the latter was significantly more prominent (Fig. 6f) . Thus, it appears that knocking down active DAPK1 (by TAT-GluN2BCTM) is much more neuroprotective than just simply uncoupling the GluN2B-DAPK1 association (by TAT-GluN2B).
Together, these data provide proof-of-concept evidence for the feasibility of our targeting peptide-based protein knockdown strategy in vivo. Furthermore, these data illustrate the possibility of achieving region-and/or disease-specific knockdown of endogenous proteins, depending on the nature of the interaction between the targeting peptide and its protein substrate. Finally, given that efficient protein knockdown was obtained following systemic application of the targeting peptide, our evidence suggests that targeting peptide may be suitable for use in designing therapeutics.
DISCUSSION
In this study, we demonstrate a new targeting peptide-based method for knocking down native proteins in vitro and in vivo. Such a method offers a robust, reversible, dose-and time-dependent and possibly conditional way to degrade native proteins. The efficient knockdown of both small (19 kDa, α-synuclein) and large (160 kDa, DAPK1) cytoplasmic proteins, as well as the synaptic scaffolding protein PSD-95 and the A53T pathological variant of α-synuclein, further demonstrate the feasibility and versatility of this targeting peptide-based method, providing proof-of-concept evidence for using it to efficiently knock down most, if not all, endogenous cytosolic proteins.
This method has several advantages over existing methods such as genetic knockout and siRNA-mediated protein knockdown. First, this method is much faster: knockdown can be realized as fast as 2 h after treatment. Such speed cannot be achieved with any previously described protein manipulations at either DNA or mRNA levels. Therefore, our method is expected to be less vulnerable to the compensation often associated with these slower DNA-or mRNAbased protein knockdown methods. Second, the reversibility and dose-dependency of our targeting peptide-based method mean that the degree and duration of the protein knockdown can be easily controlled by varying the dose and/or times of the peptide applications, thereby making it a useful and effective research tool in biomedical studies aimed at elucidating the functions of a protein in physiological processes and in the pathogenesis of diseases. Third, the peptide can be generated through several means. It can be overexpressed following cDNA plasmid transfection, expressed and purified as a recombinant protein using common bacterial expression systems, or commercially synthesized as short synthetic peptides. Therefore, it is a versatile system that can be widely used by almost any biomedical laboratory, even those without sophisticated molecular biological facilities.
Compared to recently developed protein knockdown strategies, which typically need to genetically modify target proteins to render them susceptible to regulation by cellular degradation systems [6] [7] [8] , our method enables the study of native proteins in situ without prior modification, precluding artifacts that may arise from genetically manipulating the POI. Our proof-of-concept experiments with the TAT transducing domain as the CMPD demonstrate that targeting peptides can readily cross the plasma membrane when bath-applied in primary cell cultures in vitro or given peripherally in intact animals in vivo, eliminating the need for viral infection. Indeed, we and others have previously shown that TAT can deliver biologically active cargo across the blood-brain barrier and plasma membrane into the cell interior in a highly efficient manner both in vitro and in vivo 30, 40, 41 . However, the CMPD is not limited to TAT. As Pep-1 can also efficiently deliver the targeting peptide, it appears that TAT can be replaced by alternative cell-penetrating peptides. This is especially useful in cases where covalent linkage between cell-penetrating peptide and cargo is not desirable. Compared to previous methods that use small chemicals to control protein levels 7, 11, 42 , peptides can be more easily designed to target a protein for which binding pockets amenable to small molecule inhibition cannot be found 43 . Here we have successfully designed three targeting peptide PBDs by literature search and proven their efficacy. Methods such as phage display and peptide arrays 43 can further aid the discovery of appropriate PBDs, and rational design through computational modeling may increase the specificity and affinity of a candidate PBD to its target protein.
Specificity is of upmost importance in any system designed to perturb specific protein function. In our case, the specificity and effectiveness of targeting peptide in knocking down POIs would largely depend on the specificity and affinity of the interaction between the PBD and the POI. Although peptide-protein binding is mediated by a small number of contacts formed by the residues in linear motifs, these interactions can be extremely specific 44 . In isolation, these motifs bind their target proteins with sufficient strength to establish functional interactions 44 . Furthermore, these interactions are often limited by the biological context, as seen with the interaction between DAPK1 and GluN2B, which adds another layer of specificity and control. In our tests, each targeting peptide was specific for its own intended target protein, with no off-target effects. And, notably, TAT-GluN2BCTM was specific for the active but not inactive form of DAPK1, illustrating a degree of specificity that cannot be achieved by either DNA or mRNA targeting.
Unlike other methods of protein degradation, our system utilizes the endosome-lysosome system in place of the proteasome. Like the ubiquitin-proteasome pathway, CMA activity is present under basal conditions in the brain, and it is further activated under conditions of stress 45 and proteasome inhibition 14 . Hence a CMA-based degradation system would not only complement current protein knockdown methods but also be especially powerful under pathological conditions where the cell is under stress and/or the proteasome is inhibited. The effectiveness of targeting peptides supports the conclusion that attachment of a CTM facilitates the degradation of a non-CMA protein via CMA, as previously described 14 . We further show that a targeting peptide with a CTM can also lead to degradation of its binding partner through the lysosome, regardless of the latter's endogenous route of degradation. In line with a previous study describing degradation of mutant huntingtin by viral infection of a CTM-containing adaptor protein through CMA 19 , our experiments with lysosomal and macroautophagy inhibitors and siRNA also argue for CMA as the main route of degradation. Hence an inherent limitation to our strategy is that it cannot manipulate proteins involved in the CMA machinery or lysosomal integrity. A specific case to note is that certain pathological variants of disease-causing proteins, such as A53T α-synuclein, inhibit the CMA machinery by binding tightly to the LAMP-2A receptor and precluding degradation of other CMA substrates 22 . However, we found that the α-synuclein targeting peptide was able to degrade A53T α-synuclein in a lysosomal activity-dependent manner (Supplementary Fig. 7) . Nevertheless, in cases where lysosomal activity is compromised, these problems may be overcome by harnessing the proteasomal degradation system using a similar targeting-peptide strategy. To this end, a short amino acid-based strong proteasome targeting signal has recently been described 7 . Furthermore, we can also predict that a combination of a peptide containing a CTM and one with proteasome-targeting signal peptides may dramatically enhance knockdown of certain native proteins.
npg t e C h n I C a l r e p O r t S Perhaps the greatest potential of our system, compared to previously existing methods of regulating protein abundance at either the DNA, mRNA or protein level, is its ready potential for clinical translation. In most cases, previously described protein knockdown methods require expression of a genetically modified cDNA in targeted cells with viral infection 42 and are therefore not immediately practical for therapeutic use in human patients. However, the use of the TAT cell membrane-penetrating domain in our method easily delivers the targeting peptide into the interior of cells in various organs after administration through a number of drug delivery routes, including the commonly used i.v. application. The efficacy and safety of TATmediated transduction of therapeutic peptides across the blood-brain barrier and cell membranes of neurons in the brain has recently been demonstrated in a successful phase 2B clinical trial 46 . Our proof-of-concept experiments with MCAo, a common model for focal ischemia, show that the targeting peptide is capable of knocking down death-inducing DAPK1 in the brain, but specifically in the damaged areas, leaving DAPK1 in nonischemic regions intact. The ability to achieve such a disease-related, region-specific knockdown has the obvious advantage over a general genetic ablation of DAPK1 of reducing unwanted effects. While the delivery and stability of peptides as therapeutic agents has historically been problematic, recent developments in a range of modification techniques, such as retro-inverso peptides 47 , can be applied to improve the delivery and pharmacological profile of a peptide 43 . Thus the method described here may open the possibility of developing new therapeutics, particularly for those diseases in which the pathogenesis is at least in part caused by gain of function due to an overexpression and/or mutation of a particular protein.
In summary, we present a peptide-based method that can rapidly and reversibly knock down endogenous proteins in situ. It is suitable for both in vitro and in vivo use, can be easily generalized to potentially degrade any cytosolic POI and offers a complementary approach to current genetic and chemical means of regulating the expression levels of native proteins. It should soon prove not only a powerful tool for scientific research but also a means of facilitating the development of effective therapeutics.
METHODS
Methods and any associated references are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
